These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 15785941

  • 21. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H, Sato T, Kurihara T, Kurosawa T, Fukagawa M.
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [Abstract] [Full Text] [Related]

  • 22. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism.
    Dressler R, Laut J, Lynn RI, Ginsberg N.
    Clin Nephrol; 1995 May; 43(5):324-31. PubMed ID: 7634548
    [Abstract] [Full Text] [Related]

  • 23. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study.
    Bacchini G, Fabrizi F, Pontoriero G, Marcelli D, Di Filippo S, Locatelli F.
    Nephron; 1997 May; 77(3):267-72. PubMed ID: 9375818
    [Abstract] [Full Text] [Related]

  • 24. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol.
    Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G.
    Kidney Int; 1992 Nov; 42(5):1191-8. PubMed ID: 1453603
    [Abstract] [Full Text] [Related]

  • 25. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.
    Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E.
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S48-54. PubMed ID: 9808143
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Long-term effect of intravenous calcitriol on the treatment of severe hyperparathyroidism, parathyroid gland mass and bone mineral density in haemodialysis patients.
    Huraib S, Abu-Aisha H, Abed J, Al Wakeel J, Al Desouki M, Memon N.
    Am J Nephrol; 1997 Oct; 17(2):118-23. PubMed ID: 9096441
    [Abstract] [Full Text] [Related]

  • 28. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.
    Ito H, Ogata H, Yamamoto M, Takahashi K, Shishido K, Takahashi J, Taguchi S, Kinugasa E.
    Clin Nephrol; 2009 Jun; 71(6):660-8. PubMed ID: 19473635
    [Abstract] [Full Text] [Related]

  • 29. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure.
    Ardissino G, Schmitt CP, Testa S, Claris-Appiani A, Mehls O.
    Pediatr Nephrol; 2000 Jul; 14(7):664-8. PubMed ID: 10912539
    [Abstract] [Full Text] [Related]

  • 30. Serum parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D3 in patients on maintenance haemodialysis.
    Rassoul Z, Mousa D, Rehman MA, Abdalla AH, Hawas F, Popovich W, Gaisoum M, al-Sulaiman M, Al-Khader A.
    Am J Nephrol; 1995 Jul; 15(6):507-11. PubMed ID: 8546173
    [Abstract] [Full Text] [Related]

  • 31. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J, Martin KJ, González EA, Acchiardo SR, Valdin JR, Soltanek C.
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [Abstract] [Full Text] [Related]

  • 32. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
    Tanaka M, Itoh K, Matsushita K, Matsushita K, Fukagawa M.
    Nephron Clin Pract; 2006 Oct; 102(1):c1-7. PubMed ID: 16166800
    [Abstract] [Full Text] [Related]

  • 33. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients.
    Johnson DW, Rigby RJ, McIntyre HD, Brown A, Freeman J.
    Nephrol Dial Transplant; 1996 Jan; 11(1):88-93. PubMed ID: 8649658
    [Abstract] [Full Text] [Related]

  • 34. Time course of change in calcium x phosphorus product after percutaneous ethanol injection therapy.
    Koiwa F, Hasegawa T, Kojima I, Ideura T.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii53-7. PubMed ID: 12771302
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Calcitriol dose optimization in the treatment of secondary hyperparathyroidism during dialysis. Results at 6 months].
    Rodríguez García M, Fernández Martín JL, Ruiz de Castañeda J, Hervás Sánchez J, Cannata Andía JB, Grupo de Estudio Caldial.
    Nefrologia; 2002 Jun; 22(4):370-6. PubMed ID: 12369129
    [Abstract] [Full Text] [Related]

  • 37. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study.
    Gallieni M, Cucciniello E, D'Amaro E, Fatuzzo P, Gaggiotti A, Maringhini S, Rotolo U, Brancaccio D, Collaborating nephrologists of the CARDIALISI Study Group.
    J Nephrol; 2002 Jun; 15(2):165-70. PubMed ID: 12018633
    [Abstract] [Full Text] [Related]

  • 38. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient.
    Rodriguez M, Caravaca F, Fernandez E, Borrego MJ, Lorenzo V, Cubero J, Martin-Malo A, Betriu A, Jimenez A, Torres A, Felsenfeld AJ.
    Kidney Int; 1999 Jul; 56(1):306-17. PubMed ID: 10411707
    [Abstract] [Full Text] [Related]

  • 39. Advantages of adjusting the initial dose of intravenous calcitriol according to PTH levels.
    Rodríguez-García M, Fernández-Martín JL, de Castañeda JR, Hervás-Sánchez J, Cannata-Andía JB, Caldial Study Group.
    Kidney Int Suppl; 2003 Jun; (85):S79-82. PubMed ID: 12753272
    [Abstract] [Full Text] [Related]

  • 40. Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism.
    Vlassopoulos D, Noussias C, Revenas K, Hadjilouka-Mantaka A, Arvanitis D, Tzortzis G, Hadjiconstantinou V.
    Ren Fail; 1999 Mar; 21(2):199-207. PubMed ID: 10088180
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.